TP53 and cancer: Perhaps supporting targeting abscission-control proteins for cancer therapy, the Chmp4cT232 mutation sensitizes cancer cells to replication stress by low doses of the DNA replication inhibitor aphidicolin and synergizes with loss of p53 [13].